Lipid nanoparticles (LNPs) may show excellent encapsulation in formulation buffer yet lose protection, structure, or biological performance after serum contact. Proteins, lipoproteins, ions, and enzymes can adsorb to the surface, exchange with lipids, or alter internal organization. The result may be true leakage, payload degradation, reduced recovery, or functional loss without an obvious change in encapsulation data.
A useful study must determine how much intact payload remains particle-associated, whether the particle population has changed, and whether the retained payload still produces the intended response. This guide explains the mechanisms, formulation strategies, analytical options, and troubleshooting logic used in an LNP payload retention testing program.
Encapsulation efficiency measured after preparation describes the starting formulation, not its behavior in a biological matrix. During exposure, payload can move from a protected state to a surface-accessible or free state. Nucleic acids may become vulnerable to nucleases, proteins may unfold, and small molecules may partition into serum proteins or lipoproteins. An LNP may also retain payload while losing the structure required for productive delivery.
Payload retention connects formulation composition with exposure stability and function. It helps researchers compare lipids, select PEG-lipid architectures, define handling conditions, and locate whether performance loss begins before or after uptake. It is also central to broader lipid nanoparticle stability assessment.
Table 1. Complementary Metrics for Interpreting LNP Payload Retention.
| Metric | Calculation | What It Answers | Important Limitation |
| Current encapsulated fraction | Encapsulated payload at time t / total recovered payload at time t × 100% | What fraction of the recovered payload remains particle-associated? | Can look high when total payload recovery has fallen. |
| Payload retention | Encapsulated payload at time t / encapsulated payload at time 0 × 100% | How much of the initially encapsulated payload remains? | Requires a reliable initial value and recovery correction. |
| Free payload fraction | Free payload at time t / total recovered payload at time t × 100% | Is payload becoming accessible or fully released? | Does not capture degraded payload that is no longer detected. |
| Mass balance recovery | Total recovered payload at time t / total payload at time 0 × 100% | Is material being lost through degradation, adsorption, precipitation, or sample handling? | Needs matrix-matched controls and a qualified total-payload method. |
| Functional retention | Activity after exposure / activity of the matched unexposed control × 100% | Does the exposed LNP still deliver an active payload? | Combines retention with uptake, trafficking, and intracellular release. |
No single metric is sufficient. A defensible conclusion normally combines encapsulated payload, free payload, total recovery, payload integrity, particle size, PDI, and a functional readout. This prevents a high current encapsulated fraction from masking degradation or low recovery.
Serum-induced payload loss is not a single phenomenon but a convergence of distinct mechanisms operating on overlapping timescales. Understanding which mechanism dominates in a given formulation is the prerequisite to selecting an effective corrective strategy. The five primary mechanisms are described below.
PEGylated lipids form the steric barrier that prevents LNP aggregation and limits nonspecific protein adsorption. However, PEG-lipids with short C14 hydrophobic anchors — such as DMG-PEG — undergo measurable desorption within minutes of serum exposure. Single-particle FCCS studies have quantified this phenomenon: approximately 36 ± 6% of PEG-lipid desorbs from the LNP surface with a half-life of approximately 10–11 minutes, driven primarily by serum albumin acting as a hydrophobic sink. Once the PEG shield is compromised, the underlying lipid surface becomes accessible to serum proteins, triggering a cascade of structural rearrangements that further destabilize the particle. PEG-lipids with longer C18 anchors (DSG-PEG) desorb substantially more slowly, preserving steric protection for hours rather than minutes — a parameter that should be deliberately matched to the expected circulation time.
Apolipoprotein E (ApoE) is the most consequential single serum protein for LNP fate. Upon adsorption, ApoE actively penetrates the lipid monolayer, inserting its amphipathic helices into the hydrophobic membrane interior. This disrupts lipid packing, increases membrane fluidity, and can trigger reorganization of the internal mRNA-lipid complex. The consequence is measurable mRNA release: approximately 35 ± 27% of encapsulated mRNA can be released during serum incubation, with roughly 75% of LNPs exhibiting a "step-release" pattern — a discrete burst of mRNA loss occurring approximately 8 minutes into serum exposure. Smaller LNPs are disproportionately affected because a larger fraction of their payload resides within the surface-proximal "vulnerable shell" — approximately 3–12 nm from the particle surface. An 80 nm LNP encapsulating approximately 35 mRNA molecules may lose more than half during the first 10 minutes of serum exposure, whereas a 140 nm LNP carrying approximately 200 molecules loses a more manageable fraction.
The broader protein corona — the dynamic coating of serum proteins forming within seconds of LNP introduction to blood — profoundly influences payload retention. Corona composition depends on LNP surface chemistry. Neutral, PEGylated surfaces favor ApoE adsorption, which at least provides a receptor-mediated uptake pathway via LDLR. Charged or hydrophobic surfaces attract a heterogeneous corona rich in opsonins — immunoglobulins, complement factors (C3, C4), and fibrinogen — that tag the particle for rapid clearance by Kupffer cells and splenic macrophages of the mononuclear phagocyte system (MPS). MPS-cleared particles are trafficked to phagolysosomes where both carrier and cargo are degraded — payload loss occurring not because the cargo leaked, but because the entire particle was diverted to a degradative compartment. Corona-modulating strategies — optimized PEG density, near-neutral surface charge, and particle sizing below 100 nm — are therefore integral to retention optimization.
LNPs are not static assemblies; they exist in dynamic equilibrium with their environment. Individual lipid components can partition out of the particle and into serum proteins or lipoproteins at rates determined by their hydrophobicity, charge, and molecular geometry. Ionizable lipids with shorter or unsaturated hydrophobic tails are particularly susceptible to extraction by serum albumin and high-density lipoproteins (HDL). Helper phospholipids can exchange with phospholipid pools in serum lipoproteins. Cholesterol, despite its membrane-rigidifying function, can be extracted by HDL particles — a process accelerated when the LNP membrane is already destabilized by PEG shedding or ApoE insertion. The selective loss of individual lipid species changes the compositional stoichiometry of the particle, which in turn alters its phase behavior, permeability, and capacity to retain payload. This mechanism is often overlooked because it does not produce an obvious change in particle size or PDI — the LNP may appear intact by DLS while having lost 15–20% of a critical lipid component, with corresponding degradation in retention performance.
Cryo-EM studies reveal that LNP morphology is not static during serum exposure. Particles transition from compact, electron-dense cores to less ordered structures, with bleb formation — blister-like protrusions where the lipid monolayer delaminates from the internal mRNA-lipid complex — creating aqueous channels for water, ions, and nucleases. Concurrently, ester bonds within ionizable lipids and helper phospholipids undergo gradual hydrolysis at pH 7.4, accelerated by serum esterases, while oxidative degradation of unsaturated lipid tails introduces membrane-disrupting peroxidation products. These processes are cumulative: early changes may be modest, but over hours, progressive degradation can lead to wholesale particle disintegration.
Table 2. Five Mechanisms of Serum-Induced LNP Payload Loss — Summary.
| Mechanism | Primary Driver | Timescale | Diagnostic Signature | Key Mitigation |
| PEG-Lipid Shedding | Serum albumin extraction | Minutes (t1/2 ~10 min) | Rapid initial mRNA leakage; particle aggregation | Longer PEG-lipid anchor (C18) |
| ApoE-Induced Remodeling | ApoE helix insertion into membrane | Minutes (step-release ~8 min) | Step-wise mRNA release; size-dependent vulnerability | Tighter lipid packing; phytosterol substitution |
| Protein Corona Remodeling | Opsonin adsorption; MPS recognition | Seconds to minutes | Rapid plasma clearance; liver > target signal | Neutral surface charge; PEG optimization |
| Selective Lipid Loss | HDL/albumin extraction of lipids | Minutes to hours | Stable size/PDI; declining retention | Multi-tail ionizable lipids; saturated helper lipids |
| Degradation & Morphology Change | Hydrolysis; oxidation; bleb formation | Hours | Cryo-EM blebs; progressive PDI broadening | Antioxidants; saturated lipids; lyophilization |
Addressing serum-induced payload loss requires a multi-pronged approach spanning lipid chemistry, PEG architecture, surface engineering, buffer and process optimization, and systematic stability evaluation. The strategies below are organized from the molecular to the operational level, reflecting the hierarchy of design decisions in LNP development.
The ionizable lipid is the functional core of the LNP, and its molecular structure directly determines resistance to serum-induced destabilization. Three structural features are critical: hydrophobic domain architecture (branched or multi-tail domains resist extraction by albumin and HDL); headgroup charge density (multiple ionizable amines form multidentate interactions with mRNA phosphate, increasing dissociation activation energy); and pKa optimization (apparent pKa 6.2–6.5 ensures neutrality at physiological pH while enabling endosomal protonation). LNP ionizable lipid optimization services provide systematic screening across these parameters. Cholesterol substitution represents another powerful lever: C24-alkyl phytosterols — β-sitosterol, campesterol, and stigmasterol — produce tighter lipid packing than cholesterol, reducing free volume for water penetration and ApoE insertion. β-sitosterol LNPs demonstrate reduced mRNA leakage during extended serum incubation; stigmasterol LNPs retain superior particle integrity after freeze-drying. Helper lipid selection further modulates stability: DSPC (saturated C18, Tm ≈ 55 °C) confers superior serum resistance; DOPE (unsaturated C18:1) promotes endosomal escape at the expense of serum retention. The choice depends on whether the delivery challenge is dominated by stability or intracellular release.
PEG-lipid architecture directly controls the kinetics of PEG desorption — the critical first step in the degradation cascade. Three parameters can be independently optimized: anchor length (C14 DMG-PEG desorbs with t1/2 ≈ 10–11 min; C18 DSG-PEG provides hours-long shielding); molar density (1.5–2.5 mol% provides optimal balance; below 1.0 mol% permits aggregation, above 5 mol% blocks receptor engagement); and cleavable linkages (acid-labile ester or hydrazone bonds enable selective PEG shedding in the endosomal environment). LNP PEG-lipid optimization services systematically evaluate these parameters.
Beyond PEGylation, complementary surface strategies include: zwitterionic coatings that resist protein adsorption through hydration-layer mechanisms distinct from steric repulsion; albumin-recruiting surfaces (albumin-binding lipids at 2–5 mol%) that route LNPs toward lymphatic rather than hepatic clearance; and pH-responsive charge-reversal polymers that are anionic at pH 7.4 (minimizing MPS recognition) and become cationic in the endosome (promoting membrane fusion). Nanoparticle functionalization services at BOC Sciences encompass these approaches with quantified ligand density and surface coverage.
Process parameters translate compositional potential into robust performance. N/P ratio: 4:1 to 6:1 provides sufficient electrostatic binding to resist serum dissociation while permitting cytoplasmic release; ratios above 8:1 risk the "high encapsulation, low expression" paradox. Microfluidic mixing: higher aqueous-to-organic flow rate ratios (3:1–5:1) and higher total flow rates favor homogeneous particles with narrower payload distribution. Microfluidic LNP production services with systematic parameter screening identify optimal conditions. Post-formulation stabilization: Tris buffers may provide superior pH stability; EDTA (0.1–0.5 mM) mitigates metal-catalyzed oxidation; lyophilization with sucrose or trehalose (5–20% w/v) provides robust long-term storage. Lipid nanoparticle stability assessment is essential for establishing shelf-life parameters.
Systematic serum stability evaluation should be integrated into every stage of LNP development. A tiered approach is recommended: Tier 1 (screening): RiboGreen-based retention at 0, 1, 6, and 24 hours in 50% serum at 37 °C for all formulation variants. Tier 2 (characterization): for leads, add DLS monitoring at each time point, protein corona LC-MS/MS, and cryo-EM imaging at 0 and 24 hours. Tier 3 (functional validation): for the final candidate, add dual-label flow cytometry (Cy5-mRNA/EGFP) to correlate physicochemical retention with functional delivery. This ensures stability problems are detected early, when adjustments are least costly.
BOC Sciences combines extensive LNP development experience with integrated technical capabilities to optimize formulation and process parameters for improved serum stability.
Accurate quantification of payload retention following serum exposure requires methods that unambiguously distinguish encapsulated from leaked payload while managing interference from serum components. Four complementary methodological categories address different analytical objectives.
The RiboGreen fluorescence-based dye exclusion assay remains the most widely deployed method. The fluorophore intercalates into accessible RNA but is physically excluded from RNA within intact LNPs. The standard workflow: (i) serum incubation at 37 °C for 0–72 hours; (ii) RiboGreen addition (1:200 in TE buffer, Ex 485 nm / Em 530 nm) to quantify free mRNA; (iii) surfactant disruption (Tween 20 0.5%, the preferred Triton X-100 replacement) followed by RiboGreen for total mRNA; (iv) retention calculated as (total − free) / total × 100%. Key considerations: use serum-only blank controls to correct for fluorescence quenching; recognize that RiboGreen cannot distinguish fully encapsulated from surface-associated mRNA — AEX studies confirm systematic underestimation of true encapsulation. It is useful for comparative screening but insufficient as a standalone method.
Table 3. RiboGreen Dye Exclusion Assay — Standard Workflow for Serum-Exposed LNPs.
| Step | Operation | Purpose |
| 1. Serum Incubation | LNPs with 10–50% FBS or human plasma at 37 °C, 0–72 h | Simulate in vivo exposure conditions |
| 2. Free mRNA Measurement | Add RiboGreen working solution (1:200 in TE buffer); Ex 485 nm / Em 530 nm | Quantify leaked, unencapsulated mRNA |
| 3. Total mRNA Measurement | Add Tween 20 0.5% or Triton X-100 1% to disrupt LNPs, then add RiboGreen | Quantify total mRNA in the sample |
| 4. Retention Calculation | Retention (%) = (Total mRNA − Free mRNA) / Total mRNA × 100 | Derive encapsulated fraction |
Chromatographic approaches achieve physical separation of intact LNPs from free payload. Anion Exchange Chromatography (AEX) exploits the charge difference between anionic free mRNA and near-neutral LNPs using non-porous stationary phases with glycine/NaCl gradients at pH 10.1. AEX uniquely resolves three payload states — truly free, surface-bound, and fully encapsulated — with 50-injection reproducibility of 0.28% RSD. Deformulating SEC takes the opposite approach: the mobile phase (1× PBS + 20% isopropanol + 0.2% SDS) disrupts LNPs online, enabling approximately 5-minute total payload quantification without offline preparation. Ion-Pair Reversed-Phase Chromatography (IP-RP) is valuable for multi-payload LNPs, detecting mRNA-lipid adducts alongside quantification.
Table 4. Comparison of Chromatographic Methods for LNP Payload Retention Analysis.
| Method | Separation Principle | Key Advantage | Key Limitation | Typical Run Time |
| AEX | Charge-based; preserves LNP integrity | Resolves free, surface-bound, and encapsulated mRNA | Pressure-sensitive; per-formulation optimization needed | 15–25 min |
| Deformulating SEC | Size-based; online LNP disruption | No offline preparation; high throughput | Destructive; no particle integrity information | ~5 min |
| IP-RP | Hydrophobicity-based; offline disruption | Multi-payload quantification; detects lipid adducts | Offline preparation required; 80 °C operation | ~12 min |
Integrating Sphere Scattering-Free Absorption Spectroscopy (SFA) overcomes the light-scattering limitation of conventional UV-Vis by capturing scattered light across all angles, achieving approximately 1.5% precision and approximately 5% accuracy without sample disruption — ideal for process development. Variable Pathlength UV Spectroscopy (SoloVPE) varies optical pathlength rather than diluting the sample, maintaining linearity across wide concentration ranges without calibration curves. SoloVPE excels in speed and routine analytical workflow compatibility but cannot distinguish free from encapsulated payload. The two methods complement RiboGreen: SoloVPE and SFA for rapid total RNA quantification in QC, RiboGreen for encapsulation state assessment in development.
Table 5. RiboGreen vs. SoloVPE — Complementary Roles in Payload Analysis.
| Attribute | RiboGreen | SoloVPE |
| Detection Principle | Fluorescence — dye binding to free RNA | UV 260 nm absorbance |
| Reference Standard Required | Yes | No |
| Sample Preparation | Surfactant disruption required | Minimal — no disruption needed |
| Concentrated Sample Compatibility | No — signal saturation necessitates dilution | Yes |
| Encapsulation Efficiency Assessment | Yes | No |
| Calibration Curve Required | Yes (often multiple curves) | No |
| Chemical Disruption Required | Yes | No |
| Turnaround Time | Moderate to long | Rapid |
| Routine Testing Suitability | Complex and variable | High — simple, reproducible, rapid |
Dual-Label Flow Cytometry using Cy5-labeled EGFP mRNA simultaneously tracks cellular uptake (Cy5) and successful translation (EGFP). Four-quadrant analysis distinguishes unproductive uptake (Cy5+/EGFP−) from functional delivery (Cy5+/EGFP+), providing a "functional payload retention" metric integrating all upstream loss mechanisms. Gel Retardation Electrophoresis on 2% agarose (80 V, 30 min) provides rapid semi-quantitative assessment: intact LNP-mRNA complexes are retained in the well while free mRNA migrates into the gel. While lacking chromatographic precision, it serves as an effective first-line screening tool.
If no existing method can reliably determine whether your LNP releases its payload during serum exposure, tell us about your analytical challenges and project requirements. BOC Sciences can support assay selection, method development, and customized analysis to distinguish encapsulated payload from leaked or degraded material.
When a formulation fails to meet serum retention targets, the pattern of failure — as revealed by the combination of retention data, particle sizing, and payload integrity analysis — points toward the underlying mechanism and the appropriate corrective action. Five common failure patterns are described below, each with its diagnostic signature and recommended intervention.
Observation: RiboGreen-measured retention drops from >90% to<70% over 24 hours of serum incubation, yet DLS shows no significant change in Z-average diameter or PDI. Likely cause: Selective lipid component loss (Mechanism 4) or ApoE-induced membrane remodeling (Mechanism 2) without wholesale particle disintegration. Recommended intervention: (1) Select ionizable lipids with branched or multi-tail hydrophobic domains that resist albumin/HDL extraction. (2) Replace cholesterol with β-sitosterol or stigmasterol for tighter lipid packing. (3) If DOPE is contributing to permeability, partially or fully substitute with DSPC. (4) Evaluate C18 PEG-lipid anchors if C14 anchors are in use.
Observation: Retention declines concurrently with an increase in Z-average diameter (e.g., from 80 nm to >120 nm) and/or PDI broadening (from<0.1 to="">0.2). Likely cause: PEG-lipid shedding (Mechanism 1) leading to loss of colloidal stability, with aggregation accelerating MPS clearance. Recommended intervention: (1) Increase PEG-lipid molar percentage from<1.5 mol% to 1.5–2.5 mol%. (2) Switch from C14 to C18 PEG-lipid anchor. (3) Screen buffer ionic strength and pH. (4) Verify colloidal stability in serum-free buffer — some formulations aggregate upon simple PBS dilution.
Observation: The sum of free and encapsulated mRNA after serum incubation is substantially less than the total mRNA at time zero — payload appears to have "disappeared." Likely cause: Enzymatic degradation of leaked mRNA by serum nucleases. Leakage is occurring but the released mRNA is immediately degraded, so RiboGreen registers only the net reduction in total recovery. Recommended intervention: (1) Include RNase inhibitor in the incubation medium to obtain an accurate leakage measurement (diagnostic only). (2) Confirm with AEX chromatography, which detects partially degraded mRNA fragments. (3) Target the leakage mechanism itself — inhibiting serum nucleases is not a viable in vivo strategy.
Observation: RiboGreen retention remains above 85%, but extracted mRNA shows significant degradation by capillary electrophoresis — smearing, fragment accumulation, or loss of the full-length band. Likely cause: The LNP membrane excludes RiboGreen but water, ions, and reactive oxygen species have penetrated the particle interior, initiating hydrolytic and oxidative mRNA degradation. This failure is invisible to dye exclusion assays. Recommended intervention: (1) Tighten lipid packing through phytosterol substitution and saturated helper lipids. (2) Include EDTA (0.1–0.5 mM) to chelate metal ions. (3) Evaluate lyophilization for long-term storage. (4) Add mRNA integrity analysis (capillary electrophoresis) to routine stability panels.
Observation: Physicochemical retention by RiboGreen is >80%, particle size/PDI are within specification, and mRNA appears intact — yet cellular transfection efficiency is substantially reduced versus the same formulation tested without serum pre-incubation. Likely cause: The protein corona acquired during serum incubation alters the LNP's cell-interaction properties. ApoE content may be reduced, or PEG desorption — while insufficient to cause aggregation or leakage — may have altered endosomal escape competence. Recommended intervention: (1) Characterize corona composition by LC-MS/MS after serum incubation. (2) Verify whether heat inactivation of serum is denaturing ApoE — a common artifact producing misleadingly pessimistic in vitro results. (3) Evaluate PEG-lipid architecture for the intended circulation time. (4) Consider acid-degradable lipid nanoparticles with pH-responsive shedding to preserve endosomal escape after serum exposure.
Table 6. Troubleshooting Guide — Failure Patterns, Causes, and Interventions.
| Failure Pattern | Key Observation | Most Likely Mechanism | First-Line Intervention |
| Retention drops; size/PDI stable | Leakage without aggregation | Lipid extraction or ApoE remodeling | Phytosterol substitution; multi-tail ionizable lipid |
| Retention drops; size/PDI increase | Leakage with aggregation | PEG-lipid shedding | C18 PEG-lipid; increase PEG density |
| Total recovery drops; free fraction unchanged | "Disappearing" payload | Nuclease degradation of leaked mRNA | Add RNase inhibitor (diagnostic); address leakage root cause |
| Retention high; mRNA integrity low | Encapsulated but degraded | Water/ion penetration; hydrolysis | EDTA; phytosterol; lyophilization |
| Retention acceptable; transfection reduced | Physicochemically intact but functionally impaired | Corona shift or PEG desorption | Corona LC-MS/MS; acid-cleavable PEG-lipid |
BOC Sciences provides systematic troubleshooting and optimization services to diagnose and resolve payload retention failures across the full range of LNP compositions and payload types.
BOC Sciences provides integrated services spanning the LNP development and characterization workflow, with specialized capabilities for serum stability and payload retention optimization — from rapid compositional screening and systematic formulation optimization to detailed retention characterization and root-cause troubleshooting.
BOC Sciences offers lipid nanoparticle formulation services encompassing all compositional variables evaluated through DoE approaches. Our LNP lipid library screening services provide access to diverse ionizable and helper lipid libraries. Ionizable lipid nanoparticles with tailored pKa and hydrophobic domain architectures are developed through systematic screening. Our targeted LNP development platform integrates ligands into serum-stable designs, and lipid nanoparticle manufacturing process development preserves stability through scale-up.
Our lipid nanoparticle characterization platform includes RiboGreen-based retention testing, chromatographic methods (AEX, SEC, IP-RP), and SoloVPE. Payload retention testing for LNP encapsulation with customizable serum conditions provides physiologically relevant stability data. Troubleshooting services for LNP encapsulation provide systematic investigation and resolution. Nanoparticle drug release profiling and nanoparticle cellular uptake testing provide functional validation.
Lipid nanoparticle stability services encompass storage stability (4 °C, room temperature, −20 °C, −80 °C), freeze-thaw cycling, in-use stability, and serum exposure stability assessment. LNP encapsulation efficiency optimization addresses N/P ratio screening, microfluidic parameter optimization, and buffer/excipient screening. For programs requiring lyophilized formulations, cryoprotectant screening (sucrose, trehalose, 5–20% w/v) with post-reconstitution characterization is available. LNP process optimization services translate formulation-level stability into robust, scalable manufacturing processes.
Table 7. BOC Sciences Services for LNP Serum-Exposure Retention Studies.
| Service Category | Specific Services | Key Deliverables | Inquiry |
| Formulation Screening | DoE-based lipid composition screening; ionizable lipid library screening; phytosterol substitution evaluation; helper lipid optimization | Ranked formulation leads with EE%, retention, size, PDI, and transfection data | Inquiry |
| PEG-Lipid Engineering | Anchor length screening (C14–C18); PEG density titration (0.5–5 mol%); cleavable linker evaluation; shedding kinetics measurement | Optimized PEG architecture; stability-uptake correlation data; shedding half-life | Inquiry |
| Retention Testing | RiboGreen-based time-course retention; AEX chromatography; deformulating SEC; mRNA integrity analysis; protein corona LC-MS/MS | Time-course retention curves; multi-method comparison; corona composition report | Inquiry |
| Troubleshooting | Root cause analysis for retention failure; mechanism identification; corrective formulation design; verification batch testing | Diagnostic report with identified mechanism; reformulation recommendations; verification data | Inquiry |
| Stability Assessment | Storage stability; freeze-thaw; lyophilization optimization; in-use stability; serum exposure stability | Stability-indicating assay data; recommended storage conditions; lyophilization protocol | Inquiry |
| Functional Validation | Dual-label flow cytometry (Cy5-mRNA/EGFP); transfection efficiency; cellular uptake quantification; retention-function correlation | Uptake and expression data; functional retention metrics; formulation ranking by biological endpoint | Inquiry |
LNP payload retention during serum exposure is shaped by deshielding, protein adsorption, lipid exchange, remodeling, exposure, and degradation. Reliable evaluation requires more than one encapsulation value. Free and retained payload, recovery, molecular integrity, particle structure, and function should be interpreted together. Matching methods to the payload and using failure-pattern troubleshooting reveals whether the main limitation is formulation chemistry, PEG-lipid behavior, process history, matrix interference, or downstream delivery. BOC Sciences provides integrated study design, method development, optimization, characterization, and functional evaluation for more interpretable serum-exposure performance.
